Becton Dickinson - BDX Enterprise Value-to-Revenue Multiple

bd.com (BDX) - corporate logo

The medtech industry has reached maturity, where margin growth for Becton Dickinson & Co (BDX) depends on plant automation. Global leadership and strict FDA control create a robust defensive barrier, while skilled management successfully implements new technologies. The EV/Sales ratio, which drives this chart via GURU.Markets data, demonstrates business resilience, while the value of 3622.57 expresses the level of the enterprise value-to-revenue metric.

BDX: BD Company Value to Revenue 11/23/2025 - 11/20/2026

Becton, Dickinson and Company - analytical breakdowns and key metrics (BDX)

- market value and analyst target forecast:
Fundamental company valuation:BDX, Becton Dickinson & Co
Original product of BD

Investors are assessing the resilience of Becton Dickinson & Co (BDX) by analyzing revenue dependence on government procurement and medtech regulatory cycles. For this model, it is critical to understand how market capitalization plus net debt aligns with actual sales volume. By analyzing the EV/Sales chart, you determine the business premium adjusted for leverage, which allows for the identification of fundamental undervaluation or bubble risk.

Competitor analysis for Becton Dickinson & Co

ISRG - EV/Sales Multiple|DHR: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple STERIS PLC (STE)|Enterprise Value-to-Revenue Ratio West Pharmaceutical Services|Company Value to Revenue Ratio BAX (Baxter International)|Enterprise Value-to-Revenue Ratio Masimo (MASI)|Stevanato Group - Company Value to Revenue Ratio|Enterprise Value-to-Revenue Ratio Teleflex Inc. TFX|Enterprise Value-to-Revenue Coefficient MMSI (Merit Medical Systems, Inc.)|NVST - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio ICU Medical Corp ICUI|XRAY: EV/Sales Multiple|LMAT (LeMaitre Vascular, Inc.) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue ATRC|STAA (STAAR Surgical) - Enterprise Value-to-Revenue Coefficient|Enterprise Value-to-Revenue Ratio ChromaDex (NAGE)|Company Value to Revenue ZimVie Inc. ZIMV|EV/Sales Multiple ANGO (angiodynamics.com)|EV/Sales Multiple cerus.com CERS|teknova.com - EV/Sales Multiple|Enterprise Value-to-Sales Ratio Monogram Technologies Inc. (MGRM)|Sharps Technology, Inc. (STSS) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple InfuSystem Inc (INFU)|UTMD (Utah Medical Products Inc.) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple KORU Medical Systems KRMD|Enterprise Value-to-Revenue Ratio Nyxoah SA (NYXH)|Enterprise Value-to-Revenue Coefficient MBOT|EV/Sales Multiple PDEX (Pro-Dex Inc.)|Enterprise Value-to-Revenue Coefficient ZTEK (Zentek Limited)|elutia.com - EV/Sales Multiple|Business Value to Revenue MLSS (milestonescientific.com)|NXGL (NEXGEL Inc.) - Company Value to Revenue|Retractable Technologies - Business Value to Revenue|Enterprise Value-to-Revenue Ratio harvardbioscience.com|Femasys Corp (FEMY) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple MHUA|Predictive Oncology Inc. - Company Value to Revenue Ratio|EV/Sales Multiple CJMB (Callan JMB Inc)|EV/Sales Multiple Atrion Corp ATRI|NeuroMetrix Corporation - EV/Sales Multiple